HEMISPHERX BIOPHARMA TO BEGIN AMPLIGEN TRIAL

A A

Hemispherx Biopharma has reported that it will begin an Ampligen immunopotentiation clinical trial. The Phase II clinical trial will be conducted in Australia.

Recent preclinical studies suggest that Ampligen, an experimental immunotherapeutic, may achieve at least two major therapeutic benefits when co-administered with other influenza vaccines.